Cited by 869Computational Drug Discovery MethodsDrug Solubulity and Delivery SystemsChemical Synthesis and Analysis

The DOI matches its Crossref record; 289 of the 295 references it cites were found in a registry or an index.

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Open access

Doak, Bradley Croy, Over, Bjӧrn, Giordanetto, Fabrizio, Kihlberg, Jan·2014·Chemistry & Biology

DOI 10.1016/j.chembiol.2014.08.013

Open this paper in CoChat — free account Open PDF

Abstract

The rule of 5 (Ro5) is a set of in silico guidelines applied to drug discovery to prioritize compounds with an increased likelihood of high oral absorption. It has been influential in reducing attrition due to poor pharmacokinetics over the last 15 years. However, strict reliance on the Ro5 may have resulted in lost opportunities, particularly for difficult targets. To identify opportunities for oral drug discovery beyond the Ro5 (bRo5), we have comprehensively analyzed drugs and clinical candidates with molecular weight (MW) > 500 Da. We conclude that oral drugs are found far bRo5 and properties such as intramolecular hydrogen bonding, macrocyclization, dosage, and formulations can be used to improve bRo5 bioavailability. Natural products and structure-based design, often from peptidic leads, are key sources for oral bRo5 drugs. These insights should help guide the design of oral drugs in bRo5 space, which is of particular interest for difficult targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2014.08.013

Cites

289 of 289 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,455
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J. A., & Humblet, C. C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,614
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,776
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties
Ertl, P., Rohde, B., & Selzer, P. M. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,149

Show all 295 references

Research works printed but not linked: 1

Bilello, J.P., Dousson, C.B., Colla, M.L., Chapron, C., Bhadresa, S., Camire, M., Serra, I., Gillum, J.M., Lallos, L.B., McCarville, J.F., et al. (2011). Antiviral and Preclinical Profiles of HCV NS5A Inhibitors IDX380 and IDX719. Proceedings of the 18th International Symposium on Hepatitis C Virus and Related Viruses, Seattle; September 8–12, 2011.

Sorted by citations

Items 201–300 of 869

Designing small molecules for therapeutic success: A contemporary perspective
Maurer, T. S., Edwards, M. P., Hepworth, D., Verhoest, P. R., & Allerton, C. M. N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.017 · Cited by 39
Bioisostere Effects on the EPSA of Common Permeability-Limiting Groups
Ecker, A. K., Levorse, D. A., Victor, D. A., & Mitcheltree, M. J. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00114 · Cited by 35
DBPP-Predictor: a novel strategy for prediction of chemical drug-likeness based on property profiles
Gu, Y., Wang, Y., Zhu, K., Li, W., Liu, G., & Tang, Y. (2024) · Journal of Cheminformatics · doi:10.1186/s13321-024-00800-9 · Cited by 35
“Though these rules of thumb were questioned recently [13–15], they paved the way for the development of more comprehensive drug-like indicators.”
Background
Prediction of Chameleonic Efficiency
David, L., Wenlock, M. C., Barton, P., & Ritzén, A. (2021) · ChemMedChem · doi:10.1002/cmdc.202100306 · Cited by 34
Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
Sokkar, P., Harms, M., Stürzel, C. M., Gilg, A., Kızılsavaş, G., Raasholm, M., Preising, N., Wagner, M., Kirchhoff, F., Ständker, L., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02638-5 · Cited by 34
Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases
Andrews, M. D., Dack, K. N., de Groot, M. J., Lambert, M., Sennbro, C. J., Larsen, M., & Stahlhut, M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00422 · Cited by 34
Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5
Sebastiano, M. R., Jiménez, D. G., Vallaro, M., Caron, G., & Ermondi, G. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00774 · Cited by 34
Design Principles for Balancing Lipophilicity and Permeability in beyond Rule of 5 Space
Möbitz, H. (2023) · ChemMedChem · doi:10.1002/cmdc.202300395 · Cited by 40
Advances in Lead Generation
Holenz, J., & Stoy, P. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.001 · Cited by 34
New role for crinamine as a potent, safe and selective inhibitor of human monoamine oxidase B: In vitro and in silico pharmacology and modeling
Naidoo, D., Roy, A., Slavětínská, L. P., Chukwujekwu, J. C., Gupta, S., & Staden, J. V. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112305 · Cited by 33
Design concepts for DNA-encoded library synthesis
Zhang, Y., & Clark, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116189 · Cited by 33
Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design
Yokoo, H., Shibata, N., Endo, A., Ito, T., Yanase, Y., Murakami, Y., Fujii, K., Hamamura, K., Saeki, Y., Naito, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01206 · Cited by 33
Property-Based Drug Design Merits a Nobel Prize
Pennington, L. D., Hesse, M. J., Koester, D. C., McAtee, R. C., Qunies, A. M., & Hu, D. X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01345 · Cited by 35
Cell-permeable chameleonic peptides: Exploiting conformational dynamics in de novo cyclic peptide design
Ramelot, T. A., Palmer, J. M., Montelione, G. T., & Bhardwaj, G. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102603 · Cited by 36
Small molecule-mediated protein knockdown as a new approach to drug discovery
Tinworth, C. P., Lithgow, H., & Churcher, I. (2016) · MedChemComm · doi:10.1039/c6md00347h · Cited by 32
Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation
Santana-Romo, F., Lagos, C. F., Duarte, Y., Castillo, F., Moglie, Y., Maestro, M., Charbe, N., & Zacconi, F. C. (2020) · Molecules · doi:10.3390/molecules25030491 · Cited by 29
An analysis of the physicochemical properties of oral drugs from 2000 to 2022
Pirie, R., Stanway‐Gordon, H. A., Stewart, H. L., Wilson, K. L., Patton, S., Tyerman, J., Cole, D. J., Fowler, K., & Waring, M. J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00160e · Cited by 36
Hitting Undruggable Targets: Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology
Atangcho, L., Navaratna, T. A., & Thurber, G. M. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.008 · Cited by 33
Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro , and Preclinical Models
Price, E., Kalvass, J. C., DeGoey, D. A., Hosmane, B. S., Doktor, S. Z., & Desino, K. E. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00669 · Cited by 31
Conformational Effects on the Passive Membrane Permeability of Synthetic Macrocycles
Rzepiela, A. A., Viarengo‐Baker, L. A., Tatarskii, V., Kombarov, R. V., & Whitty, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02090 · Cited by 30
Lipid Composition Is Critical for Accurate Membrane Permeability Prediction of Cyclic Peptides by Molecular Dynamics Simulations
Sugita, M., Fujie, T., Yanagisawa, K., Ohue, M., & Akiyama, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00931 · Cited by 31
Going Viral: An Investigation into the Chameleonic Behaviour of Antiviral Compounds
Wieske, L. H. E., Atilaw, Y., Poongavanam, V., Erdélyi, M., & Kihlberg, J. O. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202202798 · Cited by 30
Self-citation
Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design
Cecchini, C., Tardy, S., & Scapozza, L. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.341 · Cited by 31
Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degrader
Ermondi, G., Jiménez, D. G., Sebastiano, M. R., Kihlberg, J. O., & Caron, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010272 · Cited by 30
“Most PROTACs do not respect Lipinski’s Rule of 5 (Ro5) [5], but reside in the so-called beyond-the-Rule-of-5 (bRo5) chemical space [1,3,6,7].”
BackgroundSelf-citation
Synthesis, anti-inflammatory activity, inverse molecular docking, and acid dissociation constants of new naphthoquinone-thiazole hybrids
Efeoğlu, Ç., Taskin, S., Selcuk, Ö., Celik, B., Tumkaya, E., Ece, A., Sarı, H., Seferoğlu, Z., Ayaz, F., & Nural, Y. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117510 · Cited by 30
Computational identification of potential inhibitors targeting cdk1 in colorectal cancer
Ogbodo, U. C., Enejoh, O. A., Okonkwo, C. H., Gnanasekar, P., Gachanja, P. W., Osata, S. W., Atanda, H. C., Iwuchukwu, E. A., Achilonu, I., & Awe, O. I. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1264808 · Cited by 30
“Despite the fact that natural products frequently violate these rules due to their complexity, they still serve as reliable sources for novel drug discovery and development (Doak et al., 2014).”
Background
In vivo modulation of ubiquitin chains by N -methylated non-proteinogenic cyclic peptides
Rogers, J. M., Nawatha, M., Lemma, B. E., Vamisetti, G. B., Livneh, I., Barash, U., Vlodavsky, I., Ciechanover, A. J., Fushman, D., Suga, H., et al. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00179a · Cited by 31
Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis
Fu, C., Tsai, H., Chen, W., Chang, T., Chen, C.-L., Hsiao, P., & Li, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01477 · Cited by 31
Antibacterial Nanomaterials: Mechanisms, Impacts on Antimicrobial Resistance and Design Principles
Xie, M., Gao, M., Yun, Y. S., Malmsten, M., Rotello, V. M., Zbořil, R., Akhavan, O., Kraskouski, A. N., Amalraj, J., Cai, X., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202217345 · Cited by 30
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies
Romanov‐Michailidis, F., Hsiao, C., Urner, L. M., Jerhaoui, S., Surkyn, M., Miller, B., Vos, A. M., Blanco, M. D., Bueters, R., Vinken, P., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01953 · Cited by 29
Methods to identify and optimize small molecules interacting with RNA (SMIRNAs)
Ursu, A., Vézina‐Dawod, S., & Disney, M. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.019 · Cited by 31
Molecular dynamics simulations reveal the inhibitory mechanism of Withanolide A against α-glucosidase and α-amylase
Oyewusi, H. A., Wu, Y. S., Safi, S. Z., Wahab, R. A., Hatta, M. H. M., & Batumalaie, K. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2104375 · Cited by 29
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologically Based Models? A Feasibility Study Based on 12 Development Compounds
Parrott, N. J., Manevski, N., & Olivares‐Morales, A. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00350 · Cited by 29
Combining Chemical Protein Synthesis and Random Nonstandard Peptides Integrated Discovery for Modulating Biological Processes
Saha, A., Suga, H., & Brik, A. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00178 · Cited by 31
Copper-Catalyzed Benzylic C–H Cross-Coupling Enabled by Redox Buffers: Expanding Synthetic Access to Three-Dimensional Chemical Space
Chen, S.-J., Krska, S. W., & Stahl, S. S. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00580 · Cited by 29
Reliable and Performant Identification of Low-Energy Conformers in the Gas Phase and Water
Cavasin, A. T., Hillisch, A., Uellendahl, F., Schneckener, S., & Göller, A. H. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00151 · Cited by 29
The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline
Apprato, G., Ermondi, G., & Caron, G. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00231 · Cited by 30
Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing pathways in neurodegenerative disorders and cancer
Kaushik, A., Parashar, S., Ambasta, R. K., & Kumar, P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102279 · Cited by 30
The changing landscape of medicinal chemistry optimization
Rácz, A., Mihalovits, L. M., Beckers, M., Fechner, N., Stiefl, N., Sirockin, F., McCoull, W., Evertsson, E., Lemurell, M., Makara, G. M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01225-1 · Cited by 42
“In particular, the eRo5 property space 34,35 has been shown to be a rich source of permeable and orally bioavailable compounds 36 .”
Analysis of solvent-exposed and buried co-crystallized ligands: a case study to support the design of novel protein–protein interaction inhibitors
Trisciuzzi, D., Nicolotti, O., Miteva, M. A., & Villoutreix, B. O. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.013 · Cited by 28
Application of Negative Design To Design a More Desirable Virtual Screening Library
Yang, Z., He, J.-H., Lü, A., Hou, T., & Cao, D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01476 · Cited by 29
Natural phyto, compounds as possible noncovalent inhibitors against SARS-CoV2 protease: computational approach
Ogidigo, J. O., Iwuchukwu, E. A., Ibeji, C. U., Okpalefe, O. A., & Soliman, M. E. S. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1837681 · Cited by 28
“Lipinski’s RO5 states that for a drug to be orally active, it must have an HBD count of 5 and HBA of 10 (Doak et al., 2014).”
Background
A Brief Review of Machine Learning-Based Bioactive Compound Research
Park, J., Beck, B. R., Kim, H. H., Lee, S.-B., & Kang, K. (2022) · Applied Sciences · doi:10.3390/app12062906 · Cited by 30
“In fact, a major source of oral drugs is derived from NPs [11].”
Background
Local Delivery of Therapeutics to the Cochlea Using Nanoparticles and Other Biomaterials
Dash, S., Zuo, J., & Steyger, P. S. (2022) · Pharmaceuticals · doi:10.3390/ph15091115 · Cited by 30
“Molecules that fail to follow one or more of these rules may have difficulty with bioavailability [56].”
Background
Natural product-based PROteolysis TArgeting Chimeras (PROTACs)
Liu, M., Martyn, A. P., & Quinn, R. J. (2022) · Natural Product Reports · doi:10.1039/d2np00038e · Cited by 29
Advances in Anticancer Alkaloid-Derived Metallo-Chemotherapeutic Agents in the Last Decade: Mechanism of Action and Future Prospects
Ansari, M. F., Khan, H. Y., Tabassum, S., & Arjmand, F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108335 · Cited by 28
Explore drug-like space with deep generative models
Wang, J., Mao, J., Wang, M., Le, X., & Wang, Y. (2023) · Methods · doi:10.1016/j.ymeth.2023.01.004 · Cited by 31
Computational allosteric ligand binding site identification on Ras proteins
McCarthy, M. J., Prakash, P., & Gorfe, A. A. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv100 · Cited by 29
“In short, HTVS requires a careful selection of a small-molecule ligand library [72], which involves among other things setting up criteria for molecular size, solubility, and cell permeability [73 – 75].”
Method
Flexibility-tuning of dual-display DNA-encoded chemical libraries facilitates cyclic peptide ligand discovery
Petrov, D. D., Plais, L., Schira, K., Cai, J., Keller, M., Lessing, A., Bassi, G., Cazzamalli, S., Neri, D., Gloger, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58507-w · Cited by 31
Human topoisomerase inhibition and DNA/BSA binding of Ru(II)–SCAR complexes as potential anticancer candidates for oral application
Grandis, R. A. D., de Camargo, M. S., da Silva, M. M., Lopes, É. O., Padilha, E. C., Resende, F. A., Peccinini, R. G., Pavan, F. R., Desideri, A., Batista, A. A., et al. (2017) · BioMetals · doi:10.1007/s10534-017-0008-z · Cited by 27
“Indeed, the relationship between log P and oral absorption undoubtedly merits the consideration of the charge of ionizable groups of compounds that plays a key role as far as the membrane permeation rate is concerned (Veber et al. 2002; Doak et al. 2014).”
Background
Chemical structure modifications and nano‐technology applications for improving ADME‐Tox properties, a review
Farouk, F., & Shamma, R. N. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201800213 · Cited by 28
An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma
Lupien, L. E., Dunkley, E. M., Maloy, M. J., Lehner, I. B., Foisey, M. G., Ouellette, M. E., Lewis, L. D., Pooler, D. B., Kinlaw, W. B., & Baures, P. W. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258947 · Cited by 27
“Only the rotatable bonds are outside of the parameters favored for smallmolecule drug discovery, while the intramolecular hydrogen bond formed in this scaffold is recognized as a beneficial feature in the design of orally available drugs (Doak et al., 2014).”
Background
Co-delivery of allergen epitope fragments and R848 inhibits food allergy by inducing tolerogenic dendritic cells and regulatory T cells
Hong, J., Xiao, X., Gao, Q., Li, S., Jiang, B., Sun, X., Ran, P., & Yang, P. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s215415 · Cited by 27
“For many peptide drugs larger than 1000 Da, the optimized delivery systems are necessary to enhance the peptide permeation across the physiological barriers.(16) mPEG-PDLLA could also act as highly effective peptide delivery systems and offer multiple advantages, such as the function to control and extend the release…”
Background
Exploring resveratrol dimers as virulence blocking agents – Attenuation of type III secretion in Yersinia pseudotuberculosis and Pseudomonas aeruginosa
Sundin, C., Zetterström, C. E., Vo, D. D., Brkljača, R., Urban, S., & Elofsson, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-58872-0 · Cited by 27
Screening for Inhibitors of Main Protease in SARS-CoV-2: In Silico and In Vitro Approach Avoiding Peptidyl Secondary Amides
Yamamoto, K. Z., Yasuo, N., & Sekijima, M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01087 · Cited by 27
Computer aided drug design in the development of proteolysis targeting chimeras
Tunjic, T. M., Weber, N., & Brunsteiner, M. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.02.042 · Cited by 29
Applications of machine learning in microbial natural product drug discovery
Arnold, A., Alexander, J., Liu, G., & Stokes, J. M. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2251400 · Cited by 30
“However, NP drugs often violate Lipinski’s rules, and confining NP-like chemical libraries to these rules could limit their structural diversity [110].”
BackgroundMethod
Leveraging chromatography based physicochemical properties for efficient drug design
Goetz, G. H., & Shalaeva, M. Y. (2018) · ADMET & DMPK · doi:10.5599/admet.529 · Cited by 26
“Reprinted from [36] Copyright (2014), with permission from Elsevier.”
BackgroundMethodInfluential
“Flexible-Acceptor” General Solubility Equation for beyond Rule of 5 Drugs
Avdeef, A., & Kansy, M. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00689 · Cited by 27
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Kuemper, S., Cairns, A. G., Birchall, K., Yao, Z., & Large, J. M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1370509 · Cited by 32
“Additionally, increased efflux is common in bRo5 (Doak et al., 2014; Matsson et al., 2016; Cantrill et al., 2020; Cox et al., 2023) and PROTAC development space (Klein et al., 2021).”
Influential
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
Hayhow, T. G., Williamson, B., Lawson, M., Cureton, N., Braybrooke, E. L., Campbell, A., Carbajo, R. J., Cheraghchi-Bashi, A., Chiarparin, E., Diène, C. R., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06238-x · Cited by 27
Macrocyclization strategy for improving candidate profiles in medicinal chemistry
Darlami, O., Pun, R., Ahn, S., Kim, S., & Shin, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116501 · Cited by 28
ERAP Inhibitors in Autoimmunity and Immuno-Oncology: Medicinal Chemistry Insights
Fougiaxis, V., He, B., Khan, T., Vatinel, R., Koutroumpa, N.-M., Afantitis, A., Lesire, L., Sierocki, P., Deprez, B. P., & Deprez-Poulain, R. F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00840 · Cited by 25
Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities
Yang, F., Shan, P., Zhao, N., Ge, D., Zhu, K., Jiang, C., Li, P., & Zhang, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.027 · Cited by 26
Cheminformatics Analysis and Modeling with MacrolactoneDB
Zin, P. P. K., Williams, G. J., & Ekins, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-63192-4 · Cited by 26
A comprehensive review of the strategies to improve oral drug absorption with special emphasis on the cellular and molecular mechanisms
Padhye, T., Maravajjala, K. S., Swetha, K. L., Sharma, S., & Roy, A. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102178 · Cited by 28
Type S Non‐Ribosomal Peptide Synthetases for the Rapid Generation of Tailormade Peptide Libraries**
Abbood, N., Vo, T. D., Watzel, J., Bozhüyük, K. A. J., & Bode, H. B. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202103963 · Cited by 27
High-Quality Conformer Generation with CONFORGE: Algorithm and Performance Assessment
Seidel, T., Permann, C., Wieder, O., Kohlbacher, S. M., & Langer, T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00563 · Cited by 33
Design, in silico studies, and synthesis of new 1,8-naphthyridine-3-carboxylic acid analogues and evaluation of their H1R antagonism effects
Gurjar, V. K., & Pal, D. (2020) · RSC Advances · doi:10.1039/d0ra00746c · Cited by 26
Today’s drug discovery and the shadow of the rule of 5
Young, R. J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2228199 · Cited by 26
“It is the parameter most often ‘violated’ [16] and is used to describe Extended Rule of 5 ‘space’ (eRo5, MW 500 to 700 Da) and ‘Beyond the Rule of 5’ (bRo5, MW 700+ Da) [19,20], which are the characteristics of an expanding”
Beyond the Arbitrariness of Drug-Likeness Rules: Rough Set Theory and Decision Rules in the Service of Drug Design
Miebs, G., Mielniczuk, A., Kadziński, M., & Bachorz, R. A. (2024) · Applied Sciences · doi:10.3390/app14219966 · Cited by 31
Specific Interactions between Rifamycin Antibiotics and Water Influencing Ability To Overcome Natural Cell Barriers and the Range of Antibacterial Potency
Pyta, K., Janas, A., Skrzypczak, N., Schilf, W., Wicher, B., Gdaniec, М., Bartl, F. J., & Przybylski, P. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00176 · Cited by 25
Multimodal small-molecule screening for human prion protein binders
Reidenbach, A. G., Mesleh, M. F., Casalena, D. E., Vallabh, S. M., Dahlin, J. L., Leed, A., Chan, A. I., Usanov, D. L., Yehl, J., Lemke, C. T., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014905 · Cited by 26
Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors
Argikar, U. A., Blatter, M., Bednarczyk, D., Chen, Z., Cho, Y. S., Doré, M., Dumouchel, J. L., Ho, S. B., Hoegenauer, K., Kawanami, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01068 · Cited by 25
Oral delivery of biomacromolecules by overcoming biological barriers in the gastrointestinal tract: an update
Liu, S., Wen, X., Zhang, X., & Mao, S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2231343 · Cited by 25
“…2+ and disrupt actin; phosphorylate intracellular proteins can affect the junction complex and regulate the tightness of the paracellular barrier; tumor necrosis factor-α (TNF-α) can cause the actin-myosin ring more tighten, open paracellular pathway, and allow the macromolecules to penetrate [41].”
Background
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106847 · Cited by 26
FMO-guided design of darunavir analogs as HIV-1 protease inhibitors
Chuntakaruk, H., Hengphasatporn, K., Shigeta, Y., Aonbangkhen, C., Lee, V. S., Khotavivattana, T., Rungrotmongkol, T., & Hannongbua, S. V. (2024) · Scientific Reports · doi:10.1038/s41598-024-53940-1 · Cited by 25
Stack-HDAC3i: A high-precision identification of HDAC3 inhibitors by exploiting a stacked ensemble-learning framework
Shoombuatong, W., Meewan, I., Mookdarsanit, L., & Schaduangrat, N. (2024) · Methods · doi:10.1016/j.ymeth.2024.08.003 · Cited by 24
Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability
Poongavanam, V., Peintner, S., Abeje, Y. E., Kölling, F., Meibom, D., Erdélyi, M., & Kihlberg, J. O. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00068 · Cited by 24
Self-citation
Ribosomal Synthesis of Macrocyclic Peptides with β2- and β2,3-Homo-Amino Acids for the Development of Natural Product-Like Combinatorial Libraries
Adaligil, E., Song, A., Hallenbeck, K. K., Cunningham, C. N., & Fairbrother, W. J. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00062 · Cited by 24
Are we ready to design oral PROTACs®?
Jiménez, D. G., Sebastiano, M. R., Caron, G., & Ermondi, G. (2021) · ADMET & DMPK · doi:10.5599/admet.1037 · Cited by 24
“Then, after recalling the concept of chemical space and tailoring to bRo5 molecules [18], we built a PROTAC® chemical space based on the aforementioned descriptors and investigated their distribution in relation to a set of oral available bRo5 drugs.”
Method
In Silico Prediction of Anti-Infective and Cell-Penetrating Peptides from Thalassophryne nattereri Natterin Toxins
de Cena, G. L., Scavassa, B. V., & Conceição, K. (2022) · Pharmaceuticals · doi:10.3390/ph15091141 · Cited by 24
“562, consistent with values for approved peptide drugs and small molecule drugs [96,100].”
BackgroundInfluential
Using filters in virtual screening: A comprehensive guide to minimize errors and maximize efficiency
Mahgoub, R. E., Atatreh, N., & Ghattas, M. A. (2022) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2022.09.002 · Cited by 24
Identification, In-Vitro Anti-Plasmodial Assessment and Docking Studies of Series of Tetrahydrobenzothieno[2,3-D]Pyrimidine-Acetamide Molecular Hybrids as Potential Antimalarial Agents
Pal, K., Raza, M. K., Legac, J., Rahman, A., Manzoor, S., Bhattacharjee, S., Rosenthal, P. J., & Hoda, N. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115055 · Cited by 25
Ligandability and druggability assessment via machine learning
Palma, F. D., Abate, C., Decherchi, S., & Cavalli, A. (2023) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1676 · Cited by 26
Natural product drug discovery and drug design: two approaches shaping new pharmaceutical development
Tzvetkov, N. T., Kirilov, K., Matin, M., & Atanasov, A. G. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad208 · Cited by 24
Divergent Solid‐Phase Synthesis of Natural Product‐Inspired Bipartite Cyclodepsipeptides: Total Synthesis of Seragamide A
Arndt, H., Rizzo, S., Nöcker, C., Wakchaure, V. N., Milroy, L. ‐., Bieker, V. C., Calderon, A., Tran, T. T. N., Brand, S., Dehmelt, L., et al. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201500368 · Cited by 24
Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products
O’Hagan, S., & Kell, D. B. (2020) · Marine Drugs · doi:10.3390/md18110582 · Cited by 23
Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases
Griesenauer, R. H., Schillebeeckx, C., & Kinch, M. S. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.010 · Cited by 23
Molecular Dynamics Simulation Studies of Bile, Bile Salts, Lipid-Based Drug Formulations, and mRNA–Lipid Nanoparticles: A Review
Guruge, A. G., Warren, D. B., Pouton, C. W., & Chalmers, D. K. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00049 · Cited by 24
The microtubule cytoskeleton: A validated target for the development of 2-Aryl-1H-benzo[d]imidazole derivatives as potential anticancer agents
Park, S. J., Song, I., Yeom, G. S., & Nimse, S. B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116106 · Cited by 23
Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors
Prachayasittikul, V., Worachartcheewan, A., Toropova, A. P., Toropov, A. A., Schaduangrat, N., Prachayasittikul, V., & Nantasenamat, C. (2017) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2016.1264468 · Cited by 23
“the rule of five may lead to a loss of opportunity in finding potential compounds acting on difficult targets [56].”
BackgroundInfluential
Macrocycle Cell Permeability Measured by Solvation Free Energies in Polar and Apolar Environments
Kamenik, A. S., Kraml, J., Hofer, F., Waibl, F., Quoika, P. K., Kahler, U., Schauperl, M., & Liedl, K. R. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00280 · Cited by 23
Design strategies for organelle-selective fluorescent probes: where to start?
Alamudi, S. H., & Lee, Y. (2025) · RSC Advances · doi:10.1039/d4ra08032g · Cited by 23
“54 These  ndings indicate that the observations made by Pye et al. 53 extend beyond the speci  c cyclic peptides studied and are applicable to various types of cell-permeable molecules.”
Isolation and in silico prediction of potential drug-like compounds from Anethum sowa L. root extracts targeted towards cancer therapy
Saleh‐E‐In, M. M., Roy, A., Al-Mansur, M. A., Hasan, C. M., Rahim, M. M., Sultana, N., Ahmed, S., Islam, M. R., & Staden, J. V. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.11.025 · Cited by 22
Protein-coated corrole nanoparticles for the treatment of prostate cancer cells
Soll, M., Chen, Q., Zhitomirsky, B., Lim, P. P., Termini, J. S., Gray, H. B., Assaraf, Y. G., & Gross, Z. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0288-x · Cited by 22
On the design of lead-like DNA-encoded chemical libraries
Castan, I. F. S. F., Graham, J. S., Salvini, C. L. A., Stanway‐Gordon, H. A., & Waring, M. J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116273 · Cited by 22
On modeling and utilizing chemical compound information with deep learning technologies: A task-oriented approach
Lim, S., Lee, S., Piao, Y., Choi, M., Bang, D., Gu, J., & Kim, S. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.049 · Cited by 23
“Recent studies reported that there are drugs like Atazanavir, Erythromycin, or Sirolimus that disobey the RO5 in extended/beyond the RO5 space [9,10].”
Background
A comparative study of 5- fluorouracil, doxorubicin, methotrexate, paclitaxel for their inhibition ability for Mpro of nCoV: Molecular docking and molecular dynamics simulations
Singh, M. B., Vishvakarma, V. K., Lal, A. A., Chandra, R., Jain, P., & Singh, P. (2022) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2022.100790 · Cited by 21
“Hydrogen bond acceptor (HBA) and hydrogen bond donor (HBD) are also important factors for drug molecules and its values range is less than 5 for HBD and less than 10 for HBA [58].”
Challenges of Aufheben to Promote Druglikeness: Chemical Modification Strategies to Improve Aqueous Solubility and Permeability
Ishikawa, M., Tomoshige, S., & Sato, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00287 · Cited by 26

Authors: Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J.
Affiliations: Uppsala University (SE)
Corresponding author: Kihlberg, Jan
ORCID: Doak, Bradley Croy
Giordanetto, Fabrizio
Kihlberg, Jan
Venue: Chemistry & Biology
Publisher: Elsevier BV
Published: 2014-09
Volume: 21
Issue: 9
Pages: 1115-1142
ISSN: 1074-5521 (ISSN-L)
DOI: 10.1016/j.chembiol.2014.08.013
OpenAlex: W2106605095
Cited by: 835
References: 295
Citations by year: 2026: 101 · 2025: 82 · 2024: 103 · 2023: 111 · 2022: 103 · 2021: 88 · 2020: 65 · 2019: 50 · 2018: 51 · 2017: 27 · 2016: 37 · 2015: 14
FWCI: 2.15
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: public-domain
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 382 d)
Locations: Chemistry & Biology (publishedVersion, public-domain)
PubMed (publishedVersion)
Funders: AstraZeneca
Uppsala Universitet
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: Rule of 5, oral bioavailability, drug discovery, molecular weight, intramolecular hydrogen bonding, macrocyclization, oral dosage forms, natural products, structure-based drug design, pharmacokinetics, clinical candidates
MeSH terms: Administration, Oral, Biological Products, Pharmaceutical Preparations, Humans, Molecular Weight, Protease Inhibitors, Databases, Factual, Drug Delivery Systems, Macrocyclic Compounds, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks